Step Pharma is a pioneer of CTPS1 inhibition, a new approach with the potential to yield a highly selective, safe and effective cancer treatment for both blood cancers and solid tumours.
Step Pharma has unlocked the de novo pyrimidine synthesis pathway – a challenge which has eluded cancer researchers for years. We have demonstrated that all cancers are addicted to CTPS1, meaning that Step Pharma’s approach may be used to treat many different types of cancer.
Our novel approach could see the highly selective treatment of cancer without the significant side effects associated with current and emerging cancer therapies.
Driven by our deep understanding of CTPS1 biology and nucleotide synthesis, Step Pharma has discovered STP938, a first-in-class, highly selective, orally bioavailable CTPS1 inhibitor which is poised to enter clinical development in 2022. It is a targeted therapy that kills cancer cells while leaving healthy cells unharmed.
STP938 is a potent, highly selective, orally bioavailable CTPS1 inhibitor with greater than a 1,000 selectivity for human CTPS1 over CTPS2. STP938 binds to each monomer of CTPS1 mimicking CTP and thus inhibits the enzymatic activity of CTPS1.
3D crystal structure showing STP938 bound to CTPS1.
Our lead CTPS1 inhibitor STP938 has the potential to become a key treatment for a multitude of cancers and has recently entered clinical development for the treatment of blood cancers.
STP938 has the potential to become a key treatment for a multitude of cancers and could also form the backbone of various treatment regimens for solid tumors. It has recently entered clinical development for the treatment of blood cancers, with the potential for accelerated approval from a single arm Phase II study.